Current status of immunological approaches for the treatment of prostate cancer.

Current Opinion in Urology
Charles G Drake, Emmanuel S Antonarakis

Abstract

The recent Food and Drug Administration approval of sipuleucel-T for metastatic castration-resistant prostate cancer and of the anticytotoxic T-lymphocyte antigen 4 antibody (Ipilimumab) for metastatic melanoma has led to a renewed interest in immunotherapy for prostate and other cancers. Ipilimumab has entered phase III testing for prostate cancer, as has a viral-based anti-prostate-specific antigen vaccine (ProstVac-VF). Complementing these phase III studies are a number of innovative phase II studies, aimed at bringing immunotherapy forward in the setting of less advanced disease, as well as a number of interesting trials combining immunotherapy with conventional therapy for prostate cancer. Although a number of immunotherapy trials have been initiated, few mature results are available at the current time. These data are likely to mature in the setting of an increasingly complex treatment paradigm in which multiple hormonal and novel agents are available. Immunotherapy for prostate cancer represents an attractive treatment approach, with the currently available agent sipuleucel-T providing a significant survival benefit without appreciable toxicity. Novel approaches to improve the efficacy of this and other immune-active age...Continue Reading

References

Dec 6, 2001·Proceedings of the National Academy of Sciences of the United States of America·M MercaderE D Kwon
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil H BanderStanley J Goldsmith
Jun 4, 2005·Advances in Experimental Medicine and Biology·A Karolina PaluckaJacques Banchereau
Jun 16, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Jeanny B Aragon-ChingJames L Gulley
Jun 5, 2008·The Journal of Clinical Investigation·Laurence ZitvogelGuido Kroemer
Jun 25, 2009·Expert Opinion on Investigational Drugs·Ravi A MadanJames L Gulley
Jun 26, 2009·Journal of Immunological Methods·Philippe O GannonFred Saad
Jul 29, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Douglas G McNeelGeorge Wilding
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip W KantoffWayne R Godfrey
Apr 24, 2010·Nature Reviews. Immunology·Louis M WeinerShangzi Wang
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Jul 14, 2010·Expert Review of Vaccines·Sheeba Alam, Douglas G McNeel
Jul 24, 2010·Nature Reviews. Immunology·Charles G Drake
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Nov 16, 2010·Seminars in Oncology·Axel HoosRachel Humphrey
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Aug 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles J Ryan, Donald J Tindall
Sep 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan J Lipson, Charles G Drake

❮ Previous
Next ❯

Citations

Sep 8, 2012·Biologics : Targets & Therapy·Aijaz ParrayMohammad Saleem
Apr 9, 2013·Journal of Oral Microbiology·Carla CuginiMary E Davey
Mar 31, 2015·Seminars in Cancer Biology·Dass S VinayByoung S Kwon
May 29, 2014·Clinical Journal of Oncology Nursing·Rajni KannanStephanie Andrews
Dec 10, 2020·Journal for Immunotherapy of Cancer·Carolina TiraboschiDaniel Compagno
Nov 5, 2014·Cancer Immunology Research·Jonathan W Simons

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.